Gene Therapy · us
No More Rebuilding a Therapy for Every Rare Disease: VESSEL Aims to Turn Vascular Gene Editing Into a Shared Platform
The U.S. ARPA-H is investing up to $25.8 million to support a research team integrating base editing, vascular-targeted delivery, and an umbrella trial framework; the real test is whether this cross-disease blueprint can be advanced into a safe, repeatable clinical process.
The challenge of rare inherited vascular diseases lies not only in the small number of patients, but also in the fact that each mutation may force researchers to redesign the drug, validation methods, and clinical trial. Led by Massachusetts General Hospital, the VESSEL program is seeking to change this “one disease, one drug” development model: first establish a reusable vascular gene-editing platform, then swap out the editing components for different diseases, allowing multiple ultra-rare diseases to share part of the technical and evidentiary foundation.
Data from the U.S. Advanced Research Projects Agency for Health (ARPA-H) show that the contract, which is part of the THRIVE program, is worth up to $25.8 million, with Patricia L. Musolino serving as principal investigator and a support period of up to five years. External reports further indicate that the program’s implementing parties will contribute $11.2 million in matching funds, including $10.2 million from ANGEA Biotherapeutics and $1 million from private donations; this funding structure currently appears mainly in syndicated reports of content released by the hospital.
The technical core of VESSEL is delivering next-generation base editors into the vascular smooth muscle cells and endothelial cells that cause disease. Base editing can rewrite specific bases without creating typical DNA double-strand breaks, but whether an editor can reach the correct tissue has long been a major bottleneck for in vivo gene editing. The team is therefore placing nonviral delivery systems and vascular-targeting capabilities within the same development framework, with the hope that in the future only the editing payload will need to be adjusted, rather than building an entire delivery vehicle from scratch for each disease.
The initial disease areas include multisystemic smooth muscle dysfunction syndrome, generalized arterial calcification of infancy, and Sturge–Weber syndrome. These diseases can lead to childhood stroke, aneurysms, or cardiovascular events. Existing care largely focuses on symptoms and complications, with no disease-modifying therapies approved by the U.S. Food and Drug Administration that target the underlying disease-causing genes.
The program also does not limit the “platform” to the editing tools themselves. ARPA-H says the team will establish in vitro three-dimensional human vascular models and biomarker-based rapid testing strategies, with the aim of shortening the validation process and reducing reliance on time-consuming animal studies. It will also plan an umbrella clinical trial; frameworks for regulatory and stakeholder collaboration; and a network for inherited vascular diseases. If established, different diseases may be able to share safety monitoring, manufacturing standards, and some review materials under the same trial framework.
However, what has been announced so far is a research contract and development blueprint, not evidence of efficacy. Publicly available information has not yet provided animal treatment results, human dosing, off-target editing data, or a timeline for candidate products to enter clinical trials, nor has it explained the extent to which three-dimensional vascular models can replace animal studies. Blood vessels are distributed throughout the body, so if delivery is imprecise or the duration of editing is uncontrolled, safety risks could also span multiple organs. Whether the same platform can share regulatory evidence across different mutations, cell types, and stages of disease will still need to be answered through subsequent experiments and interactions with regulatory authorities.